Zinc Absorption From Zinc Citrate, Zinc Gluconate and Zinc Oxide
This study has been completed.
Sponsor:
Prof. Michael B. Zimmermann
Collaborator:
University of Zurich
Information provided by (Responsible Party):
Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology
ClinicalTrials.gov Identifier:
NCT01576627
First received: April 4, 2012
Last updated: January 3, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this trial is to evaluate zinc citrate, a zinc compound with promising sensory properties and a high zinc content, as an alternative zinc compound to be used for supplementation or food fortification. The bioavailability of zinc citrate given as a supplement to young Swiss adults will be assessed and compared to the bioavailability of the commonly used zinc compounds zinc gluconate and zinc oxide.
| Condition | Intervention |
|---|---|
|
Healthy |
Dietary Supplement: zinc citrate Dietary Supplement: Zinc Gluconate Dietary Supplement: Zinc oxide |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | Zinc Absorption From Zinc Supplements Comparing Zinc Citrate to Zinc Gluconate and Zinc Oxide in Young Adults |
Resource links provided by NLM:
MedlinePlus related topics:
Dietary Supplements
Drug Information available for:
Sodium gluconate
Sodium citrate
Zinc oxide
Zinc gluconate
Manganese gluconate
U.S. FDA Resources
Further study details as provided by Swiss Federal Institute of Technology:
Primary Outcome Measures:
- Fractional absorption of zinc [ Time Frame: 61 days ] [ Designated as safety issue: No ]Fractional absorption of zinc is estimated by using the double isotope tracer ratio technique by administering 67Zn as oral and 70Zn as intravenous stable isotopes.The urinary enrichment with both isotopes is measured in a spot urine sample by inductively coupled plasma mass spectrometry.
| Enrollment: | 15 |
| Study Start Date: | March 2012 |
| Study Completion Date: | November 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: zinc citrate |
Dietary Supplement: zinc citrate
10 mg of zinc as either zinc citrate
|
| Active Comparator: zinc gluconate |
Dietary Supplement: Zinc Gluconate
10 mg of zinc as either zinc gluconate
|
| Active Comparator: zinc oxide |
Dietary Supplement: Zinc oxide
10 mg of zinc as either zinc oxide
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female of 18 to 45 years old
- Body Mass Index in the range of 19 to 25
- No mineral and vitamin supplements two weeks prior to the study and during the whole duration of the study
Exclusion Criteria:
- Any metabolic, gastrointestinal or chronic disease (according to the subjects own statement)
- Long-term medication during the whole study (except for contraceptives)
- Vegans
- Pregnancy
- Lactation
- Intention to become pregnant during the course of the study
- Lack of safe contraception
- Consumption of mineral and vitamin supplements within 2 weeks prior to 1st test supplement administration
- Earlier participation in any nutrition study using Zn stable isotopes as well as participation in any other clinical study within the last 30 days and during this study
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Prof. Michael B. Zimmermann, Prof, Swiss Federal Institute of Technology |
| ClinicalTrials.gov Identifier: | NCT01576627 History of Changes |
| Other Study ID Numbers: | HNL/CTC11-12 |
| Study First Received: | April 4, 2012 |
| Last Updated: | January 3, 2013 |
| Health Authority: | Switzerland: Ethikkommission |
Additional relevant MeSH terms:
|
Citric Acid Zinc Zinc Oxide Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Chelating Agents Molecular Mechanisms of Pharmacological Action |
Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs Dermatologic Agents Sunscreening Agents Radiation-Protective Agents Protective Agents |
ClinicalTrials.gov processed this record on June 17, 2013